JeffreyMarkSilberbergMD

Oncology • Freehold, NJ

Hematologic Oncology

Specializes in Hematology/Oncology affiliated with Bayshore Community Hospital and Centrastate Medical Center.

Join to view full profile

Dr. Silberberg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Silberberg's full profile

Already have an account?

Office
495 Iron Bridge Rd
Ste 14
Freehold, NJ 07728
Phone+1 732-431-8400

Fax+1 732-431-0114

Education & Training

Stony Brook Medicine/University HospitalFellowship, Hematology and Medical Oncology, 1983 - 1984
George Washington UniversityFellowship, Hematology and Medical Oncology, 1981 - 1983
SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 1978 - 1981
New York University School of MedicineClass of 1978

Certifications & Licensure

NY State Medical License 1980 - 2026
NJ State Medical License 1989 - 2025
MD State Medical License 1982 - 1983
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) Start of enrollment: 2006 Apr 07
ACTIVE_NOT_RECRUITING
PHASE3
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jul 19
COMPLETED
PHASE3
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma Start of enrollment: 2008 Jul 28
ACTIVE_NOT_RECRUITING
PHASE3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
ACTIVE_NOT_RECRUITING
PHASE3
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy Start of enrollment: 2011 Jan 18
Completed
Phase 2
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
ACTIVE_NOT_RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

106 citations
Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.
Alexa B. Schrock, Viola W. Zhu, Wen-Son Hsieh, Russell Madison, Benjamin Creelan
Journal of Thoracic Oncology. 2018-09-01

Professional Memberships

American Society of Clinical Oncology - ASCO
Member